What factors are associated with a shorter time interval to prostate-specific antigen (PSA) failure (PSA nadir plus 2 ng/mL or initiation of salvage therapies) in nonmetastatic unfavorable-risk prostate cancer? This evidence concerns the gene KLK3 and prostate cancer.